| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BMS-270394 | CTRPv2 | pan-cancer | AAC | -0.0088 | 0.8 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0079 | 0.8 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | 0.0075 | 0.8 |
| mRNA | PDMP | CTRPv2 | pan-cancer | AAC | 0.0086 | 0.8 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | 0.0082 | 0.8 |
| mRNA | Curcumin | CTRPv2 | pan-cancer | AAC | 0.0076 | 0.8 |
| mRNA | Epothilone B | FIMM | pan-cancer | AAC | 0.045 | 0.8 |
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | 0.0077 | 0.8 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | 0.0083 | 0.8 |